A Wind Turbine Tower Design Based on the Use of Fibre-Reinforced Composites.

Abstract not availableJRC.G-Institute for the Protection and the Security of the Citizen (Ispra

Gaia Early Data Release 3: The celestial reference frame (Gaia-CRF3)

Context. Gaia-CRF3 is the celestial reference frame for positions and proper motions in the third release of data from the Gaia mission, Gaia DR3 (and for the early third release, Gaia EDR3, which contains identical astrometric results). The reference frame is defined by the positions and proper motions at epoch 2016.0 for a specific set of extragalactic sources in the (E)DR3 catalogue. Aims. We describe the construction of Gaia-CRF3 and its properties in terms of the distributions in magnitude, colour, and astrometric quality. Methods. Compact extragalactic sources in Gaia DR3 were identified by positional cross-matching with 17 external catalogues of quasi-stellar objects (QSO) and active galactic nuclei (AGN), followed by astrometric filtering designed to remove stellar contaminants. Selecting a clean sample was favoured over including a higher number of extragalactic sources. For the final sample, the random and systematic errors in the proper motions are analysed, as well as the radio-optical offsets in position for sources in the third realisation of the International Celestial Reference Frame (ICRF3). Results. Gaia-CRF3 comprises about 1.6 million QSO-like sources, of which 1.2 million have five-parameter astrometric solutions in Gaia DR3 and 0.4 million have six-parameter solutions. The sources span the magnitude range G = 13-21 with a peak density at 20.6 mag, at which the typical positional uncertainty is about 1 mas. The proper motions show systematic errors on the level of 12 μas yr-1 on angular scales greater than 15 deg. For the 3142 optical counterparts of ICRF3 sources in the S/X frequency bands, the median offset from the radio positions is about 0.5 mas, but it exceeds 4 mas in either coordinate for 127 sources. We outline the future of Gaia-CRF in the next Gaia data releases. Appendices give further details on the external catalogues used, how to extract information about the Gaia-CRF3 sources, potential (Galactic) confusion sources, and the estimation of the spin and orientation of an astrometric solution

EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI) : Study protocol for a multicentre, observational trial

More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369

Produção animal e retorno econômico da suplementação em pastagem de aveia e azevém Animal production and economic return in a supplementated oats/ryegrass mixture

O experimento avaliou a resposta animal e o retorno econômico do uso da suplementação energética em pastagem de aveia preta (Avena strigosa Schreb) + azevém anual (Lolium multiflorum Lam). Os tratamentos foram: STP - Suplementação, durante todo o período de utilização da pastagem; SAS- Suplementação até final de setembro; SS- Sem suplementação. O sistema de pastejo foi o contínuo com lotação variável. O suplemento utilizado foi o grão de sorgo em quantidade variável para manter a mesma quantidade de massa de forragem em todos os tratamentos. O ganhos de peso médios diários por animal (GMD) foram superiores nos tratamentos STP e SAS, 0,716 e 0,710 kg, respectivamente, em relação ao obtido no tratamento SS (0,580 kg). A suplementação possibilitou maior carga animal. A produção animal por hectare foi maior em STP, 627 kg ha-1 de PV, sendo 75% superior aos 359 kg ha-1 de PV do SS. A suplementação não afetou a condição corporal dos animais. O custo total e a receita líquida foram de 775,42/165,08, 605,75/204,25 e 367,35/204,92 R$ha-1 para STP, SAS e SS, respectivamente. O uso exclusivo da pastagem e a suplementação, até o final de setembro, resultaram em maior retorno financeiro direto.<br>The experiment evaluated the animal response and economic return of energetic supplementation in oat (Avena strigosa Schreb) plus Italian ryegrass (Lolium multiflorum Lam) pasture. The treatments were: STP- Supplementation during the entire pasture cycle; SAS- Supplementation until the end of September and SS- No supplement. The continuous grazing system with variable stocking rate was used. The supplement utilized, with different quantities, was ground sorghum in order to maintain the same herbage mass for all treatments. Live weight daily gain was higher in STP and SAS, 0.716 and 0.710 kg, respectively than 0.580 kg in SS. The stocking rate was greater with supplements. The higher weight gain per hectare was at STP (627 kg), 75$ha for STP, SAS and SS, respectively. No supplements and the use of supplementation until the end of September resulted in higher economic return

Gaia Data Release 3: the Galaxy in your preferred colours: Synthetic photometry from Gaia low-resolution spectra

Stars and planetary system

EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): Study protocol for a multicentre, observational trial

Introduction More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. Methods and analysis EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. Ethics and dissemination EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369.